UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Database Paper--The IRI Marketing Data Set

Marketing science (Providence, R.I.), 2008-07, Vol.27 (4), p.745-748

2008

Volltextzugriff (PDF)

The IRI Marketing Data Set

Marketing science (Providence, R.I.), 2008-07, Vol.27 (4), p.745-748

2008

Volltextzugriff (PDF)

IRI: financial intermediary or entrepreneurial state?

Financial history review, 2020-12, Vol.27 (3), p.436-448

Amatori, Franco

2020

Volltextzugriff (PDF)

2022 IRI CTO Forum Summary

Research technology management, 2023-01, Vol.66 (1), p.26-29

2023

Volltextzugriff (PDF)

Development of a Brief Form of the Interpersonal Reactivity Index (B-IRI)

Journal of personality assessment, 2016-09, Vol.98 (5), p.461-471

2016

Volltextzugriff (PDF)

Performance evaluation of IRI, IRI Plas and SAMI2 during the consecutive prolonged solar minimum of cycles 23 and 24 around 100°E

Advances in space research, 2023-09, Vol.72 (5), p.1665-1687

2023

Volltextzugriff (PDF)

Obesity Aggravates Ischemia-Reperfusion Injury (IRI)-Induced AKI in Mice: SA-PO072

Journal of the American Society of Nephrology, 2022-11, Vol.33 (11S), p.621-621

2022

Volltextzugriff (PDF)

Results of a phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study)

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.655-655

2024

Volltextzugriff (PDF)

Unpublished Ration texts from Iri-Sagrig (iri-sag-rig7 ki )

Ātār al-rāfidayn (Online), 2023-06, Vol.8 (2), p.3-25

2023

Volltextzugriff (PDF)

Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS621-TPS621

2022

Volltextzugriff (PDF)

Development and validation of the Illness Representation Interview (IRI)

European psychiatry, 2024-08, Vol.67 (S1), p.S97-S98

2024

Volltextzugriff (PDF)

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS4190-TPS4190

2023

Volltextzugriff (PDF)

Do irinotecan (IRI) dose reductions driven by UGT1A128 genotyping prevent IRI-related severe neutropenia? A real-world study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e16116-e16116

2020

Volltextzugriff (PDF)

Regorafenib (REG) combined with irinotecan (IRI) versus IRI alone as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas (mGA): A randomized phase II trial (PRODIGE 58 – UCGI 35 – REGIRI)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.387-387

2023

Volltextzugriff (PDF)

1838P Do irinotecan (IRI) dose reductions driven by UGT1A128 genotyping prevent IRI-related severe neutropenia? A real-world study

Annals of oncology, 2020-09, Vol.31, p.S1056-S1056

2020

Volltextzugriff (PDF)

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS778-TPS778

2023

Volltextzugriff (PDF)

Questions and Answers From IRI's Members: What are IRI members talking about? These questions were recently posed on IRI's Community Forum

Research technology management, 2016-07, Vol.59 (4), p.61-65

2016

Volltextzugriff (PDF)

Questions and Answers From IRI's Members: What are IRI members talking about? These questions were recently posed on IRI's Community Forum

Research technology management, 2016-05, Vol.59 (3), p.65-67

2016

Volltextzugriff (PDF)

WJOG6510G: Randomized phase II of Pmab + IRI vs Cmab + IRI for KRAS WT mCRC previously treated after FU, IRI, and L-OHP

Annals of oncology, 2017-10, Vol.28 Suppl 9, p.ix74

2017

Volltextzugriff (PDF)

Questions and Answers From IRI's Members: What are IRI members talking about? These questions were recently posed on IRI's Community Forum

Research technology management, 2016-03, Vol.59 (2), p.57-61

2016

Volltextzugriff (PDF)

Developing Synthetic Approaches with Non-Innocent Metalloligands: Easy Access to IrI/Pd0 and IrI/Pd0/IrI Cores

Angewandte Chemie (International ed.), 2011-09, Vol.50 (38), p.8839-8843

International ed. in English, 2011

Volltextzugriff (PDF)

A phase II, open-label, pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4196-TPS4196

2022

Volltextzugriff (PDF)

Prevention of Ischemia-Reperfusion Injury (IRI)-Induced AKI by Maintaining Na+/K+ ATPase Activity: TH-OR03

Journal of the American Society of Nephrology, 2023-11, Vol.34 (11S), p.1-1

2023

Volltextzugriff (PDF)

Exposure to Systemic Hypoxia After Renal Ischemia Reperfusion Injury (IRI) Promotes Kidney Repair: SA-PO152

Journal of the American Society of Nephrology, 2023-11, Vol.34 (11S), p.766-766

2023

Volltextzugriff (PDF)

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS619-TPS619

2022

Volltextzugriff (PDF)

1 – 25 von 179.078

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieChain Drug Review

SpracheTschechisch

ThemaEconomics

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37.234)
Mit Volltextzugriff
(93.199)

Publikationsform

Artikel
(84.072)
Dissertationen
(48.581)
magazinearticle
(16.498)
Reviews
(8.826)
Buchkapitel
(7.479)
Newsletter-Artikel
(5.865)
Zeitungsartikel
(4.342)
Tagungsberichte
(1.948)
Texte
(753)
Bücher
(452)
Berichte
(138)
Referenzeintrag
(99)
Webseiten
(23)
Datensätze
(1)
Bilder
(1)

10 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(141.970)
Türkisch
(23.090)
Portugiesisch
(6.321)
Japanisch
(3.521)
Deutsch
(3.031)
Spanisch
(2.436)
Französisch
(1.590)
Italienisch
(788)
Latein
(538)
Niederländisch
(522)
Russisch
(459)
Chinesisch
(322)
Rumänisch
(303)
Croatian
(212)
Slowenisch
(150)
Ungarisch
(119)
Litauisch
(102)
Hindi
(79)
Koreanisch
(73)
Polnisch
(73)

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Social Sciences
(5.819)
Marketing
(5.304)
Consumers
(3.495)
Psychology
(3.148)
Education
(3.109)
Middle Eastern Studies
(2.723)
Management
(2.675)
Mathematics
(2.550)
Humans
(2.260)
Medicine
(2.131)
History
(2.023)
Political Science
(1.928)
Trends
(1.928)
Religion
(1.880)
Supermarkets
(1.848)
Statistics
(1.788)
Computer Science
(1.742)
Male
(1.717)
Near Eastern Studies
(1.664)
Empathy
(1.656)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

ProQuest Dissertations & Theses A&I
(48.567)
Nexis Uni
(31.238)
EZB Electronic Journals Library
(20.045)
EBSCOhost Business Source Ultimate
(17.750)
Publisher or Other Site
(13.240)
IngentaConnect Journals
(13.051)
JSTOR All Journals
(10.607)
IngentaConnect Journals
(7.623)
Ebook Central Perpetual and DDA
(6.166)
eBooks on EBSCOhost
(5.988)
Journals@Ovid
(4.663)
Taylor & Francis Journals Complete
(4.151)
Taylor & Francis Current Content Access
(3.976)
Taylor & Francis Journals
(3.745)
SpringerLink
(3.292)
SAGE Publications
(3.131)
Wiley Online Library Journals Frontfile Complete
(3.021)
MEDLINE
(3.020)
Literature Online (LION)
(2.777)
ScienceDirect Pay Per View(PPV) Titles
(2.345)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Women’s Wear
(3.517)
The Spectator
(2.989)
The European Magazine, And London Review
(2.850)
Women’s Wear Daily
(2.351)
The Scots Magazine, 1739-1803
(2.322)
The Athenaeum
(1.943)
Pr Newswire
(1.889)
Mmr
(1.755)
Examiner
(1.571)
Wwd
(1.562)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Database Paper--The IRI Marketing Data Set

The IRI Marketing Data Set

IRI: financial intermediary or entrepreneurial state?

2022 IRI CTO Forum Summary

Development of a Brief Form of the Interpersonal Reactivity Index (B-IRI)

Performance evaluation of IRI, IRI Plas and SAMI2 during the consecutive prolonged solar minimum of cycles 23 and 24 around 100°E

Obesity Aggravates Ischemia-Reperfusion Injury (IRI)-Induced AKI in Mice: SA-PO072

Results of a phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study)

Unpublished Ration texts from Iri-Sagrig (iri-sag-rig7 ki )

Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress

Development and validation of the Illness Representation Interview (IRI)

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

Do irinotecan (IRI) dose reductions driven by UGT1A128 genotyping prevent IRI-related severe neutropenia? A real-world study

Regorafenib (REG) combined with irinotecan (IRI) versus IRI alone as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas (mGA): A randomized phase II trial (PRODIGE 58 – UCGI 35 – REGIRI)

1838P Do irinotecan (IRI) dose reductions driven by UGT1A128 genotyping prevent IRI-related severe neutropenia? A real-world study

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study)

Questions and Answers From IRI's Members: What are IRI members talking about? These questions were recently posed on IRI's Community Forum

Questions and Answers From IRI's Members: What are IRI members talking about? These questions were recently posed on IRI's Community Forum

WJOG6510G: Randomized phase II of Pmab + IRI vs Cmab + IRI for KRAS WT mCRC previously treated after FU, IRI, and L-OHP

Questions and Answers From IRI's Members: What are IRI members talking about? These questions were recently posed on IRI's Community Forum

Developing Synthetic Approaches with Non-Innocent Metalloligands: Easy Access to IrI/Pd0 and IrI/Pd0/IrI Cores

A phase II, open-label, pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

Prevention of Ischemia-Reperfusion Injury (IRI)-Induced AKI by Maintaining Na+/K+ ATPase Activity: TH-OR03

Exposure to Systemic Hypoxia After Renal Ischemia Reperfusion Injury (IRI) Promotes Kidney Repair: SA-PO152

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

Aktive Filter

Suchergebnisse filtern